The Day In Review: Biotech Lower After Fed Decision

February 2, 2005 -- Biotech parted ways with the broad market on Wednesday, allowing market-wide indexes to move higher while biotech gave back some of its recent gains. The Centient Biotech 200 dropped 11.40 points to 3406.97. That left the CBT 200 lower by .33%, in a session where the NYSE Composite moved up .32%, and Nasdaq was higher by a nearly identical .31%. We discuss Valeant and its purchase of Xcel Pharma, the inauspicious IPO of Favrille, the spectacular, but mysterious rise of Myogen, Ivax and its positive guidance, and a bounce for StemCells...